Recent Analysts’ Ratings Changes for Guardant Health (GH)

Guardant Health (NASDAQ: GH) has recently received a number of price target changes and ratings updates:

• 6/11/2026 – Guardant Health is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $185.00 price target on the stock.
• 6/11/2026 – Guardant Health was upgraded by Royal Bank Of Canada to “moderate buy”.
• 6/8/2026 – Guardant Health had its price target raised by Mizuho from $135.00 to $175.00. They now have an “outperform” rating on the stock.
• 6/5/2026 – Guardant Health is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $165.00 price target on the stock.
• 6/5/2026 – Guardant Health is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $165.00 price target on the stock.
• 6/2/2026 – Guardant Health was upgraded by Evercore Inc from “in-line” to “outperform”. They now have a $160.00 price target on the stock.
• 6/2/2026 – Guardant Health is now covered by Wolfe Research. They set an “outperform” rating and a $150.00 price target on the stock.
• 6/1/2026 – Guardant Health was upgraded by Wolfe Research to “strong-buy”.
• 5/28/2026 – Guardant Health was downgraded by Guggenheim from “buy” to “buy”.
• 5/27/2026 – Guardant Health was given a new $160.00 price target by BTIG Research. They now have a “buy” rating on the stock.
• 5/26/2026 – Guardant Health had its price target raised by BTIG Research from $145.00 to $155.00. They now have a “buy” rating on the stock.
• 5/21/2026 – Guardant Health was given a new $127.00 price target by Piper Sandler.
• 5/21/2026 – Guardant Health had its “buy” rating reaffirmed by TD Cowen.
• 5/12/2026 – Guardant Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $135.00 price target on the stock.
• 5/8/2026 – Guardant Health had its price target raised by Barclays PLC from $115.00 to $120.00. They now have an “overweight” rating on the stock.
• 5/8/2026 – Guardant Health had its price target raised by JPMorgan Chase & Co. from $130.00 to $135.00. They now have an “overweight” rating on the stock.
• 4/21/2026 – Guardant Health had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other news, Director Meghan V. Joyce sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total value of $1,269,800.00. Following the sale, the director directly owned 11,183 shares in the company, valued at approximately $1,420,017.34. This represents a 47.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the sale, the chief executive officer owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. This represents a 4.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 449,238 shares of company stock worth $51,164,492. Insiders own 5.60% of the company’s stock.

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.